Description of Medical Areas
About the FDA Approved Listings
|
 |
Approved Drugs for Oncology
Drugs Approved in 2008
Drugs Approved in 2007
Evista (raloxifene hydrochloride); For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women; Eli Lilly; Approved September 2007
Hycamtin (topotecan); For the treatment of small cell lung cancer; GlaxoSmithKline; Approved October 2007
Ixempra (ixabepilone); For the treatment of breast cancer; Bristol Myers Squibb; Approved October 2007
Tasigna (nilotinib hydrochloride monohydrate); For the treatment of chronic myelogenous leukemia; Novartis; Approved October 2007
Torisel (temsirolimus); For the treatment of renal cell carcinoma; Wyeth Pharms; Approved May 2007
Tykerb (lapatinib); For the treatment of breast cancer; GlaxoSmithKline; Approved March 2007
Drugs Approved in 2006
Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine); For the prevention of cervical cancer associated with human papillomavirus; Merck; Approved June 2006
Sprycel (dasatinib); For the treatment of imatinib-resistant chronic myeloid leukemia; Bristol-Myers Squibb; Approved June 2006
Sutent (sunitinib); For the treatment of kidney cancer and gastrointestinal stromal tumors; Pfizer; Approved January 2006
Drugs Approved in 2005
Arranon (nelarabine); For the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma; GlaxoSmithKline; Approved October 2005
Nexavar (sorafenib); For the Treatment of Renal Cell Carcinoma; Bayer/Onyx; Approved December 2005
Drugs Approved in 2004
Alimta (pemetrexed for injection); For the treatment of malignant pleural mesothelioma; Eli Lilly; Approved February 2004
Avastin (bevacizumab); For the treatment of metastatic carcinoma of the colon or rectum; Genentech; Approved February 2004
Clolar (clofarabine); For the treatment of acute lymphoblastic leukemia in pediatric patients; Genzyme; Approved December, 2004
Erbitux (cetuximab); For the treatment of EGFR-expressing, metastatic colorectal cancer; Imclone, Bristol-Myers Squibb; Approved February 2004
Sensipar (cinacalcet); For the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients; Amgen; Approved March 2004
Tarceva (erlotinib, OSI 774); For the treatment of advanced refractory metastatic non-small cell lung cancer; Genentech, OSI Pharmaceuticals; Approved November, 2004
Drugs Approved in 2003
Aloxi (palonosetron); For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy; MGI Pharma, Helsinn Healthcare; Approved August 2003
Bexxar; For the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma following chemotherapy relapse; Corixa; Approved June 2003
Emend (aprepitant); For the treatment of nausea and vomiting associated with chemotherapy; Merck; Approved March 2003
Iressa (gefitinib); For the second-line treatment of non-small-cell lung cancer; AstraZeneca; Approved May 2003
Plenaxis (abarelix for injectable suspension); For treatment of advanced prostate cancer; Praecis Pharmaceuticals; Approved December 2003
UroXatral (alfuzosin HCl extended-release tablets); For the treatment of of the signs and symptoms of benign prostatic hyperplasia; Sanofi-Synthelabo; Approved June 2003
Velcade (bortezomib); Injectable agent for the treatment of multiple myeloma patients who have received at least two prior therapies.; Millennium Pharmaceuticals; Approved May 2003
Drugs Approved in 2002
Eligard (leuprolide acetate); For the palliative treatment of advanced prostate cancer; Atrix Laboratories; Approved January 2002
Eloxatin (oxaliplatin/5-fluorouracil/leucovorin); For the treatment of colon or rectum carcinomas; Sanofi-Synthelabo; Approved August 2002
Faslodex (fulvestrant); For the treatment of hormone receptor positive metastatic breast cancer; AstraZeneca; Approved April 2002
Gleevec (imatinib mesylate); For the treatment of gastrointestinal stromal tumors (GISTs); Novartis; Approved February 2002
Neulasta; Treatment to decrease the chance of infection by febrile neutropenia in patients receiving chemotherapy; Amgen; Approved January 2002
SecreFlo (secretin); To aid in the diagnosis of pancreatic dysfunction and gastrinoma; Repligen; Approved April 2002
Zevalin (ibritumomab tiuxetan); For the treatment of non-Hodgkin's lymphoma; IDEC Pharmaceuticals; Approved February 2002
Zometa (zoledronic acid); For the treatment of multiple myeloma and bone metastases from solid tumors; Novartis; Approved February 2002
Drugs Approved in 2001
Campath; Injectable treatment of B-cell chronic lymphocytic leukemia; Berlex Laboratories; Approved May 2001
Femara (letrozole) Tablets; First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer; Novartis; Approved January 2001
Gleevec; Oral therapy for the treatment of chronic myeloid leukemia; Novartis; Approved May 2001
Kytril (granisetron) Solution; For the prevention of nausea and vomiting associated with cancer therapy; Roche; Approved June 2001
Trelstar LA; Intramuscular injection for the treatment of advanced stage prostate cancer; Debiopharm; Approved June 2001
Xeloda; Oral chemotherapy for the treatment of metastatic colorectal cancer; Roche; Approved May 2001
Drugs Approved in 2000
Mylotarg (gemtuzumab ozogamicin); For the treatment of CD33 positive acute myeloid leukemia (AML); Wyeth Pharmaceuticals; Approved May 2000
Trelstar Depot (Injectable Triptorelin Pamoate); For the palliative treatment of advanced prostate cancer; Debio Rechereche Pharmaceutique, Target Research Associates; Approved June 2000
Trisenox (arsenic trioxide); For the induction of remission and consolidation in patients with acute promyelocytic leukemia (APL); Cell Therapeutics; Approved September 2000
Drugs Approved in 1999
Aromasin Tablets; Exemestane Tablets, 25 mg; Pharmacia & Upjohn; October 21, 1999
Busulflex; For use in combination for the treatment of leukemia; Orphan Medical; Approved February 1999
Doxil (doxorubicin HCl liposome injection); Treatment for ovarian cancer that is refractory to other first-line therapies; Alza; Approved June 1999
Ellence; epirubicin hydrochloride; Pharmacia & Upjohn; Approved September 1999
Ethyol (amifostine); Treatment for xerostomia (dry mouth) due to radiation; U.S. Bioscience, Alza; Approved June 1999
Temodar; Treatment for refractory anaplastic astrocytoma; Schering-Plough; Approved August 1999
UVADEX Sterile Solution; Treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL); Therakos; Approved February 1999
Zofran ODT; Treatment for the prevention of chemotherapy and radiation-induced nausea; GlaxoWellcome; Approved January 1999
Drugs Approved in 1998
Actiq; Treatment for Cancer Pain; Anesta Corporation; Approved November 1998
Anzemet; Treatment for the prevention of nausea and vomiting associated with chemotherapy and surgery; Hoechst Marion Roussel; Approved February 1998
Camptosar; Treatment for Colon or Rectal Cancer; Pharmacia & Upjohn; Approved October 1998
Gemzar; Treatment for Lung Cancer; Eli Lilly; Approved August 1998
Herceptin; Treatment for metastatic breast cancer; Genentech; Approved October 1998
Inform HER-2/neu breast cancer test; Treatment for breast cancer prediction; Oncor; Approved January 1998
Neupogen; Treatment for slow white blood cell recovery following chemotherapy; Amgen; Approval April 1998
Nolvadex; Treatment for Breast Cancer; Zeneca Pharmaceuticals; Approved October 1998
Photofrin; Treatment for early-stage, microinvasive endobronchial non-small cell lung cancer; QLT; Approved January 1998
Proleukin; Treatment for metastatic melanoma; Chiron Corporation; Approved January 1998
Sclerosol Intrapleural Aerosol; Treatment for malignant pleural effusions; Bryan Corporation; Approved January 1998
Valstar; Treatment for Bladder Cancer; Anthra Pharmaceuticals; Approved October 1998
Xeloda; Treatment for advanced breast cancer tumors; Roche; Approved April 1998
Zofran; Treatment for postoperative vomiting and nausea in adults; GlaxoWellcome; Approved April 1998
Drugs Approved in 1997
Anzemet; Treatment for emesis; Hoechst Marion Roussel; Approved September 1997
Bromfenac; Management of acute pain; Duract, Wyeth-Ayerst Laboratories; Approved July 1997
Femara; Treatment for breast cancer; Novartis; Approved July 1997
Gliadel Wafer (polifeprosan 20 with carmustine implant); Treatment for brain cancer; Rhone-Poulenc Rorer, Guilford Pharmaceuticals; Approved February 1997
Intron A; Treatment for non-Hodgkin's lymphoma; Schering-Plough; Approved December 1997
Kytril; Prevention of nausea and vomiting associated with chemotherapy; SmithKline Beecham; Approved November 1997
Lupron Depot; Treatment for prostate cancer; TAP Pharmaceuticals; Approved July 1997
Miraluma test; Test for breast cancer; DuPont Pharma Radiopharmaceuticals; Approved May 1997
Neumega; Treatment for thrombocytopenia; Genetics Institute; Approved November 1997
Quadramet (Samarium Sm 153 Lexidronam Injection); Treatment for pain associated with bone cancer; DuPont Merck Pharmaceutical Company; Approved March 1997
Rituxan; Treatment for non-hodgkin's lymphoma; Idec Pharmaceuticals, Genentech; Approved November 1997
Taxol; Treatment for AIDS-related Kaposi's Sarcoma; Bristol-Myers Squibb; Approved August 1997
Drugs Approved in 1996
Anexsia; Treatment for chronic pain; Mallinckrodt Group; Approved August 1996
Aredia (pamidronate disodium for injection); Treatment for osteolytic bone metastases of breast cancer; Chiron Therapeutics, Ciba Pharmaceuticals; Approved August 1996
Arimidex (anastrozole); Treatment for advanced breast cancer in postmenopausal women; Zeneca Pharmaceuticals; Approved January 1996
Camptosar Injection; Treatment for metastatic colorectal cancer; Pharmacia & Upjohn; Approved June 1996
CEA-Scan; Diagnostic imaging product for colorectal cancer; Immunomedics; Approved April 1996
|
|
Back to Centerwatch Drug Approvals
|
